Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RH020A
- Development stage
- Preclinical
- Lead developer
- Shenzhen Rhegen Biotechnology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
RH020A is a preclinical-stage in vivo chimeric antigen receptor T-cell (CAR-T) therapy being developed by Shenzhen Rhegen Biotechnology for the treatment of lupus nephritis. Unlike traditional ex vivo CAR-T therapies, which require the extraction, modification, and expansion of a patient's T cells outside the body, RH020A is designed to generate CAR-expressing T cells directly within the patient's body. This approach aims to simplify the treatment process and eliminate the pathogenic cells driving the progression of lupus nephritis. As a product from an mRNA-focused biotechnology company, RH020A likely utilizes mRNA-lipid nanoparticle (LNP) technology to transiently reprogram endogenous T cells to target disease-associated antigens.
- Other names
- In vivo CAR-T治疗狼疮肾炎
Beyond the preview
Go deeper on RH020A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RH020A.